Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, Landry J, Krull JH, Downing AM, Willis BA, Shcherbinin S, Mullen J, Barker P, Schumi J, Shering C, Matthews BR, Stern RA, Vellas B, Cohen S, MacSweeney E, Boada M, Sims JR. Wessels AM, et al. Among authors: selzler kj. JAMA Neurol. 2020 Feb 1;77(2):199-209. doi: 10.1001/jamaneurol.2019.3988. JAMA Neurol. 2020. PMID: 31764959 Free PMC article. Clinical Trial.
Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).
Sims JR, Selzler KJ, Downing AM, Willis BA, Aluise CD, Zimmer J, Bragg S, Andersen S, Ayan-Oshodi M, Liffick E, Eads J, Wessels AM, Monk S, Schumi J, Mullen J. Sims JR, et al. Among authors: selzler kj. J Prev Alzheimers Dis. 2017;4(4):247-254. doi: 10.14283/jpad.2017.38. J Prev Alzheimers Dis. 2017. PMID: 29181490 Review.
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease.
Zimmer JA, Shcherbinin S, Devous MD Sr, Bragg SM, Selzler KJ, Wessels AM, Shering C, Mullen J, Landry J, Andersen SW, Downing AM, Fleisher AS, Svaldi DO, Sims JR. Zimmer JA, et al. Among authors: selzler kj. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12123. doi: 10.1002/trc2.12123. eCollection 2021. Alzheimers Dement (N Y). 2021. PMID: 33614894 Free PMC article.
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Honig LS, et al. Among authors: selzler kj. N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971. N Engl J Med. 2018. PMID: 29365294 Free article. Clinical Trial.
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R; Alzheimer’s Disease Neuroimaging Initiative. Liu-Seifert H, et al. Among authors: selzler kj. J Alzheimers Dis. 2015;47(1):205-14. doi: 10.3233/JAD-142508. J Alzheimers Dis. 2015. PMID: 26402769 Free PMC article. Clinical Trial.
13 results